date:Mar 27, 2014
e company expects the new facility to be operational by next financial year, which would primarily be focussing on domestic as well as global market demand.
Darshan Mehta, ABLs executive director, said that the manufacturing of these gluconates was in line with the companys policy of launching value-added products regularly.
The new greenfield capacity, which is expandable and has United States Food and Drug Administration (USFDA)-approved infrastructure, would also manufacture enzymes and c